WuXi AppTec Q3 2026: 9M Revenue RMB 45.54B, Up 38.6%; Full-Year Guidance Raised to RMB 61.0–61.9B

9M total revenue RMB 45.54B and attributable net profit RMB 19.40B (+60.6%); adjusted non-IFRS net profit RMB 18.38B (+74.4%). Continuing-operations backlog crossed RMB 70B for the first time at RMB 76.74B, and the company raised full-year guidance again.

After market close on October 26, WuXi AppTec (603259.SH / 2359.HK) reported its 2026 third-quarter results: revenue, profit and cash flow all strengthened, and the company raised its full-year guidance for the third time this year.

For the first nine months of 2026, total revenue reached RMB 45.54B, up 38.6% YoY; continuing-operations revenue grew 46.3%. Adjusted non-IFRS net profit was RMB 18.38B, up 74.4%, with net margin up 8.3 ppts to 40.4%; attributable net profit under CAS was RMB 19.40B, up 60.6%. In Q3 alone, revenue was RMB 16.64B (+38.01%) and attributable net profit RMB 8.318B, up 136.67%.

Backlog and cash flow also hit records: as of end-September, continuing-operations backlog reached RMB 76.74B, up 36.4% YoY and crossing RMB 70B for the first time; adjusted operating cash flow was RMB 17.28B, up 58.9%. The company noted that 9M cumulative revenue, profit under three measures, and adjusted operating cash flow had all exceeded full-year 2025 levels.

By segment, small-molecule D&M (process R&D and manufacturing) revenue was RMB 23.58B, up 65.6%, with the D&M pipeline reaching 3,863 molecules — 103 commercial and 94 Phase III — and commercial molecules crossing 100 for the first time. The TIDES business (oligonucleotides and peptides) earned RMB 11.52B, up 46.9%, with served clients +37% and molecules +86% YoY; full-year TIDES revenue is expected at ~RMB 16.7B (+47%).

Thanks to the greater success of multiple client products, and the unique advantages of our CRDMO model with excellent global execution, we sustained our strong momentum … continuing-operations backlog reached RMB 76.7B and we further raised our full-year guidance.

On the strength of these results, the company further raised 2026 guidance: total revenue from RMB 58.5–60.5B to RMB 61.0–61.9B; continuing-operations revenue growth from 35–39% to 40–42%; capex from RMB 7.5–8.5B to RMB 8.0–8.5B (including an early start on the new Changzhou base); and adjusted free cash flow from RMB 13.5–14.5B to RMB 14.5–15.5B. For shareholder returns, cash dividends of RMB 6.22B were paid in the first nine months (RMB 4.71B 2025 final plus RMB 1.51B 2026 interim).